1. |
Germing U, Strupp C, Kungen A, et al. No increase in age-specific incidence of myelodysplastic syndromes. Haematologica, 2004, 89(8):905-910.
|
2. |
Cogle CR, Craig BM, Rollison DE, et al. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm:high number of uncaptured cases by cancer registries. Blood, 2011, 117(26):7121-7125.
|
3. |
Goldberg SL, Chen E, Corral M, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol, 2010, 28(17):2847-2852.
|
4. |
Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer, 2007, 109(9):1705-1714.
|
5. |
Neukirchen J, Blum S, Kuendgen A, et al. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes. Eur J Haematol, 2009, 83(5):477-482.
|
6. |
Garcia Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia, 2008, 22(3):538-543.
|
7. |
Jadersten M, Hellstrom-Lindberg E. Myelodysplastic syndromes:biology and treatment. J Intern Med, 2009, 265(3):307-328.
|
8. |
Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol, 1982, 51(2):189-199.
|
9. |
Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 2002, 100(7):2292-2302.
|
10. |
Mufti GJ, Steven JR, Oscier DG, et al. Myelodysplastic syndromes:a scoring system with prognostic significance. Br J Haematol, 1985, 59(3):425-433.
|
11. |
Leone G, Teofili L, Voso MT, et al. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica, 2002, 87(12):1324-1341.
|
12. |
Merlo A, Herman JG, Mao L, et al. 5_CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med, 1995, 1(7):686-692.
|
13. |
Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes:Results of a phase Ⅲ randomized study. Cancer, 2006, 106(8):1794-1803.
|
14. |
Wierda W, O Brien S, Faded S, et al. A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer, 2006, 106(2):337-345.
|
15. |
Higgins JPT, Green S(editors). Cochrane Handbook for Systematic Reviews of Interventions Version5. 1. 0[updated March 2011]. The Cochrane Collaboration, 2011. Available from:www. Cochrane-handbook. org.
|
16. |
Kantarjian H, Issa JP, Rosenfeld CS, et al. ecitabine improves patient outcomes in myelodysplastic syndromes:results of a phase Ⅲ randomized study. Cancer, 2006, 106(8):1794-1803.
|
17. |
Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy:final results of the randomized phase Ⅲ study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol, 2011, 29(15):1987-1996.
|
18. |
Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome:a study of the cancer and leukemia group B. J Clin Oncol, 2002, 20(10):2429-2440.
|
19. |
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes:a randomised, open-label, phase Ⅲ study. Lancet Oncol, 2009, 10(3):223-232.
|
20. |
Greenberg PL, Attar E, Bennett JM. NCCN Clinical practice guidelines in Oncology:Myelodysplastic Syndromes. J Natl Compr Canc Netw, 2011, 9(1):30-56.
|
21. |
Atallah E, Kantarjian H. The role of decitabine in the treatment of myelodysplastic syndromes. Expert Opin. Pharmacother, 2007, 8(1):65-73.
|
22. |
Griffiths EA. DNA Methyltransferase and Histone Deacetylase inhibitors in the treatment of Myelodysplastic Syndromes. Semin Hematol, 2008, 45(1):23-30.
|